The emergence of tumor cells with certain stem-like characteristics such as high aldehyde dehydrogenase (ALDH) activity due to ALDH1A1 expression contributes to chemotherapy resistance and tumor relapse. However, clinically applicable inhibitors of ALDH activity have not been reported. There is evidence to suggest that epigenetic regulation of stem-related genes 
Introduction
Chemotherapeutic drugs such as cisplatin have had a major impact on the therapeutic management of many tumors, and in particular in epithelial ovarian cancer (EOC) (1) . However, chemotherapy resistance is a major cause of cancer morbidity and mortality. For example, although EOC, in particular high-grade serous carcinoma (HGSC), initially respond well to platinum-based chemotherapy, relapse often occurs with decreased chemotherapy sensitivity (2) . The hypothesis that this occurs due to cancer stem-like cells (CSCs) remains controversial. However, there is substantial evidence in the literature that cells with CSC characteristics contribute to chemotherapy resistance and tumor relapse (3) . Putative EOC CSCs are typically characterized by increased aldehyde dehydrogenase (ALDH) activity with concomitant upregulation of ALDH1A1 (4) (5) (6) . ALDH activity is functionally important in EOC, as suppressing ALDH activity by knocking down ALDH1A1 has been shown to sensitize EOC cells to chemotherapy (4) . In addition, a population of normal ovarian stem cells also have increased ALDH activity (7) , further supporting its functioning in putative ovarian CSCs. Despite the mounting evidence on the critical role of ALDH1A1 in regulating CSCs (8) , the molecular mechanisms underlying its regulation remains poorly understood. Notably, clinically applicable inhibitors of ALDH activity or ALDH1A1 targeting approaches have not been reported.
Recent genome-wide next generation sequencing studies in human cancers have revealed frequent alterations in genes and proteins that are critical in regulating the epigenetic landscape of chromatin (9, 10) . This suggests that proteins encoded by these genes may be cancer therapeutic targets. Accordingly, small molecule inhibitors targeting chromatinregulating epigenetic enzymes have been developed (11) . The bromodomain and extraterminal (BET) family of proteins recognize acetylated lysine on histones through their bromodomains (12) . BET proteins control the transcription of their target genes either directly by recruiting transcriptional machinery or indirectly through involving enhancer elements in a lineage and context-specific manner (12) . Highly specific BET inhibitors are in clinical trials (13) . Pharmacological inhibitors of BET proteins have shown efficacy in the clinic in a number of pathologies most notably in cancer. There is evidence to suggest that epigenetic regulation of stem-related genes contributes to chemotherapy efficacy (14, 15) . Using unbiased approaches, here we have identified BET inhibitors as suppressors of ALDH activity that potentiate the anti-tumor effects of cisplatin in EOC.
Materials and Methods

Cell lines and Epigenetic Small Molecule Screen
Human EOC cell lines were obtained from ATCC within 3 years and were re-authenticated by The Wistar Institute's Genomics Facility at the end of experiments within last three months using short tandem repeat profiling using AmpFISTR Identifiler PCR Amplification kit (Life Technologies) and cultured as previously described (16) . The Structural Genome Consortium generously provided the epigenetic compound library. OVCAR3 cells were plated in 384-well plates and treated with serial dilutions (0 -20μM) of 24 epigenetic compounds with or without IC 20 cisplatin. Data were analyzed with GraphPad (Prism).
In situ 3C Assay
In situ Chromosome conformation capture (3C) samples were prepared as described previously with modifications (17) . Briefly, cells (5 × 10 6 ) were cross-linked with 1% formaldehyde and quenched by 2.5M glycine. Cells were collected and re-suspended in Hi-C lysis buffer (10mM Tris-HCl pH8.0, 10mM NaCl, 0.2% NP-40) with proteinase inhibitor (Sigma). The cell suspension was incubated on ice, washed with Hi-C buffer, re-suspended in 0.5% sodium dodecyl sulfate (SDS), and incubated at 65°C for 5min. After quenching the SDS, chromatin was digested overnight by MboI and then ligated. Ligated DNA was purified by using Wizard SV Gel and PCR Clean-up System (Promega). Quantitative PCR was performed by using Quantitect Probe PCR Master Mix (Qiagen) with custom probe and primers as described previously (18) . Probe and primer sequences are indicated in Table S1 .
Nascent RNA Sequencing and ChIP-seq
For nascent RNA sequencing, cells were incubated with 0.5 mM ethidium uridine (EU) and treated with 125 nM JQ1 or vehicle control for 40min. Total RNA was extracted with TRIzol reagent and RNeasy Mini Kit. The EU-labeled RNAs were biotinylated and precipitated by using the Click-it Nascent RNA Capture Kit (Life Technologies) following the manufacturer's instructions. Briefly, 5μg EU-labeled RNA was biotinylated with 0.25 mM biotin azide in Click-it reaction buffer. Biotinylated RNAs were ethanol precipitated and resuspended in ultrapure water. Biotinylated RNAs were incubated with Dynabeads MyOne Streptavidin T1 magnetic beads in Click-it RNA and subjected to library preparation. Libraries for RNA-seq were prepared with Ovation Human FFPE RNA-Seq Multiplex System 1-8 (Nugen) and sequenced on an Illumina NextSeq 500.
For ChIP-seq, cells were cross-linked with 1% formaldehyde for 10 min, followed by quenching with 125 mM glycine for 5 min. Fixed cells were resuspended in cell lysis buffer (10 mM Tris-HCl, pH7.5, 10 mM NaCl, 0.5% NP-40) and incubated on ice for 10 min. The lysates were washed with MNase digestion buffer (20 mM Tris-HCl, pH7.5, 15 mM NaCl, 60 mM KCl, 1 mM CaCl 2 ) once and incubated for 20 minutes at 37 °C in the presence of 1,000 Gel units of MNase (NEB, M0247S) in 250 μl reaction volume. After adding the same volume of sonication buffer (100 mM Tris-HCl, pH8.1, 20 mM EDTA, 200 mM NaCl, 2% Triton X-100, 0.2% Sodium deoxycholate), the lysates were sonicated for 5 min (30 secon/30 sec-off) in a Diagenode bioruptor and centrifuged at 15,000 rpm for 10 min. The cleared supernatant equivalent to 2 -4 × 10 6 cells was incubated with 2 μg of anti-BRD4 antibody (Bethyl, A301-985A) on a rocker overnight. Bound chromatin was eluted and reverse-crosslinked at 65°C overnight. For next-generation sequencing, ChIP-seq libraries were prepared from 10 ng of ChIP and input DNAs with the Ovation Ultralow DR Multiplex system (NuGEN). The ChIP-seq libraries were sequenced in a 51 base pairs paired end run using the Illumina HiSeq 2000.
In Vivo Orthotopic Xenograft Mouse Model
The Institutional Animal Care and Use Committee (IACUC) at The Wistar Institute approved all animal protocols described in this study. NOD/scid gamma (NSG) mice were injected intraperitoneally (i.p.) with OVCAR3-Luciferase cells (5 × 10 6 ). Tumors were allowed to establish for three weeks and randomized into four groups: Control (n=12), JQ1 (n=11), Cisplatin (n=12), and Cisplatin/JQ1 (n=13). Tumor growth was followed by noninvasive imaging as previously described (19) . Briefly, tumors were visualized by injecting luciferin (i.p.; 4mg/mice) re-suspended in PBS and imaged with an IVIS Spectrum. JQ1 was resuspended in 10% 2-hydroxypropyl-β-cyclodextrin solvent (Sigma-Aldrich) as previously described (20) . Cisplatin was purchased from SelleckChem and dissolved in PBS. Mice were treated daily with i.p. injections of vehicle controls and/or JQ1 (20 mg/kg) and/or biweekly with cisplatin (750 μg/kg). Tumor cells collected from peritoneal washes were incubated with ammonium chloride to lyse erythrocytes and then used for the Aldefluor assay and stained with PE-anti-mouse CD45 (BD Biosciences) antibody to exclude mouse derived hematopoietic cells. Survival of tumor-bearing mice was evaluated based on IACUC criteria.
Analysis using primary human ovarian tumors
For analyzing ALDH activity, the protocol for using the primary human ovarian tumor specimen was approved by the Wistar Institute Institutional Review Board. For expression of eRNA, BRD4 and ALDH1A1 expression, the protocol using human ovarian tumor specimens was approved by the Institutional Review Board at The M.D. Anderson Cancer Center. RNA was extracted from 26 high-grade serous ovarian tumors using the miRVana RNA isolation kit (Thermo Fisher Scientific) according to the manufacturer's protocol. Analysis of RNA levels was performed on a 7500 Fast Real-Time PCR System (Applied Biosystems) with SYBR Green-based real-time PCR using the primers as detailed in supplementary methods. Expression of β-actin was used as a housekeeping gene control. Analysis was performed using the 7500 Real-time PCR software.
Bioinformatics and Statistical Analysis
For ChIP-seq, alignment was done versus hg19 version of human genome using bowtie algorithm. BRD4 ChIP-seq for vehicle control treated cells was compared vs. input and vs. JQ1 using HOMER algorithm with "-histone" option. False discovery rate (FDR) < 1% was set as a significance threshold. RNA-seq data was aligned using bowtie2 algorithm and RSEM was used for estimating number of reads for each gene. EdgeR was used to test for differential expression and FDR <10% was used as a significance threshold unless stated otherwise. Ingenuity Pathway Analysis software was used to test gene sets for enrichment of cellular functions and canonical pathways and Ingenuity Knowledgebase was used to create regulation and protein-protein interaction network for stem-related genes. Differences in percentage between different classes were tested using Fisher Exact Test with p-value<0.05 used as a significance threshold. H3K4Me1 and H3K27Ac broad peaks were downloaded from ENCODE for GM12878, H1-hESC, HSMM, HUVEC, K562, NHEK, NHLF cell lines for overlap with BRD4 peaks. To determine the effect of combination treatment, CI (Combination Index) values were calculated by using Compusyn software (21) . CI<1, CI=1, CI>1 represent synergism, additive effect, antagonism, respectively.
Results
BET inhibitors suppress ALDH activity and inhibit ALDH1A1 expression
Since ALDH activity regulates the putative ovarian CSCs and stem-related genes are subjected to epigenetic regulation (4-6,14,15), we evaluated a panel of 24 small molecule inhibitors known to target epigenetic regulators obtained from The Structure Genomics Consortium on their ability to suppress ALDH activity ( Figure 1A and Table S2 ). We examined the expression of ALDH1A1, the major determinant of ALDH activity (4, 8) , in a panel of high-grade serous EOC cell lines (22) (Figure S1A-B) . We performed the evaluation of ALDH activity in OVCAR3 cells because these cells have high ALDH1A1 expression ( Figure S1B ). To limit the potential bias introduced by different growth inhibition potential among the small molecule inhibitors, we established a growth inhibition curve for each small molecule inhibitor and based the dose of each small molecule inhibitor on the established IC 20 value (Table S2 ). The highest tested dose (20 μM) was used for those inhibitors whose IC 20 was not achieved. Validating our experimental design, a previously reported positive regulator of ALDH activity, an HDAC inhibitor, was identified (23) . We identified four small molecule inhibitors that significantly suppressed ALDH activity ( Figure 1A-B) . Notably, all three BET inhibitors in the panel scored as "hits" that significantly suppressed ALDH activity. As JQ1 is clinically applicable (known as TEN-010 in clinical trials), we performed further validation on this inhibitor. We validated that JQ1 decreased ALDH activity in a dose-dependent manner ( Figure 1C and Figure S1C ) and in primary EOCs ( Figure 1D ). Similar results were also obtained by using I-BET 762, another BET inhibitor that is now in clinical development ( Figure 1E ). We further validated that JQ1 decreases ALDH activity of EOC cells in vivo in an orthotopic xenograft mouse model ( Figure 1F-G) . As a positive control, cisplatin increased ALDH activity in vivo as previously reported (4) . Notably, both ALDH1A1 mRNA and ALDH1A1 protein levels were decreased by JQ1 treatment in a dose-dependent manner in multiple cell lines ( Figure  1H -I and Figure S1D -E). This suggests that JQ1 decreases ALDH activity by suppressing ALDH1A1 expression at the transcriptional level.
BRD4 inhibition suppresses ALDH activity and inhibits ALDH1A1 expression
Since high ALDH activity is implicated in chemotherapy response (8), we determined whether BET inhibitors synergize with cisplatin by inhibiting ALDH activity. Indeed, JQ1 displayed a synergistic effect with cisplatin in multiple EOC cell lines (Figure 2A ). In addition, JQ1 displayed a synergistic effect with cisplatin in the in vitro derived cisplatinresistant EOC cell line A2780 CP70 ( Figure 2B ). Further, in colony formation assays, JQ1 significantly suppressed the outgrowth of EOC cells after cisplatin treatment in multiple EOC cell lines ( Figure 2C -D and Figure S2A-B) . This correlated with inhibition of ALDH activity ( Figure 2E ) and suppression of the upregulated ALDH1A1 induced by cisplatin ( Figure 2F and S2C) . We observed an increase in apoptotic markers such as cleaved caspase 3, cleaved Lamin A and cleaved PARP p85 and Annexin V in the cells treated with JQ1 and cisplatin in combination compared to either treatment alone ( Figure 2G and S2D-E) . Notably, JQ1 significantly decreased anchorage-independent sphere formation in ALDH positive cells, a characteristic of putative ovarian CSCs (24) , to a degree that is comparable to those observed in ALDH negative cells (Figure 2H-J) .
The BET family is comprised of BRD2, BRD3, BRD4 and the testis-specific BRDT proteins (12) . BRD4 is often amplified in EOC (25) . BRD4 amplification predicts a worse overall/ disease-free survival in EOC patients (26) . Consistent with a previous report (27) , we showed that BRD4 is expressed in both EOC cell lines and primary high-grade serous EOC specimens, and BRD4 knockdown suppressed the growth of EOC cells (Figure S3A-D) . Notably, cisplatin did not affect BRD4 expression ( Figure S3E 
BRD4 targets the promoters of stem-related genes
BRD4 transcriptionally regulates its target gene expression (12) . BRD4 is also known to regulate lineage-specific gene expression through enhancer elements (28) (29) (30) , which contributes to the observed specificity and selectivity of BET inhibitors. We determined whether the observed phenotypes induced by JQ1 are due to changes in BRD4 target gene expression. Nascent transcript RNA sequencing (RNA-seq) in OVCAR3 cells treated with or without JQ1 for 40 minutes was performed to identify early changes in the gene expression that are likely directly dependent on BRD4 inhibition ( Figure 4A ). In addition, BRD4 chromatin immunoprecipitation followed by next generation sequencing (ChIP-seq) analysis was performed in OVCAR3 cells treated with or without JQ1 to identify genome-wide changes in BRD4 association induced by JQ1 ( Figure 4A and S4A-B) . The nascent RNAseq and ChIP-seq data are available in the Gene Expression Omnibus (GEO) database (accession number GSE77568). ChIP-seq analysis indicated that BRD4 predominantly occupied promoter regions within 1 kb from transcription starting sites (TSS) (Figure S4A-B) . Cross-referencing of the RNA-seq and BRD4 ChIP-seq revealed that BRD4 direct target genes regulated by JQ1 treatment are significantly enriched for putative stem-related genes ( Figure 4B-C and S4C-D) . We validated three genes known to be implicated in CSCs, namely LIF (31), HES1 (32) and WNT5A (33) , as direct BRD4 targets that are downregulated by JQ1 ( Figure 4D -E and Figure S4E ). This observation correlated with a decrease in the association of BRD4 and RNA polymerase II with the promoter regions of these genes after JQ1 treatment ( Figure 4F ). These results support the notion that JQ1 may affect putative ovarian CSCs by regulating BRD4 binding to the promoters of the identified stem-related genes.
BRD4 regulates ALDH1A1 expression through a super-enhancer element and its associated enhancer RNA (eRNA)
JQ1 decreased ALDH1A1 mRNA expression (Figure 1) . However, JQ1 did not affect BRD4 binding to the ALDH1A1 promoter region ( Figure S5A ). This suggests that JQ1 regulates ALDH1A transcription through a distal regulatory element. Since BRD4 is known to regulate super-enhancer elements (28-30), we examined the role of JQ1 in regulating superenhancers through BRD4 ( Figure 5A ). To do so, we focused on BRD4 binding regions that were enriched at least 4-fold compared to input DNA and were significantly reduced by JQ1 treatment (>2-fold, p<0.05). In addition, we prioritized the list by focusing on BRD4 binding regions that spanned >10 kb and with no known genes located within at least 100 kb. We then overlapped these regions with ENCODE ChIP-seq data and considered only BRD4 binding regions that overlapped with the enhancer H3K4Me1/H3K27Ac histone marks. Our prioritization resulted in a list of 11 candidate BRD4 binding sites similar to those previously described for super-enhancers (Table S3) (28) . Interestingly, one of the potential super-enhancers is 491 kb upstream of the ALDH1A1 gene (Table S3 ). Based on RNA-seq analysis, this region is bi-directionally transcribed into RNA albeit with low reads (Figure 5B ), which is also a known feature of super-enhancers (34, 35) . We validated that JQ1 treatment decreased the expression of the RNA transcribed from the super-enhancer element (eRNA) ( Figure 5C ). This decrease in eRNA expression significantly correlated with the decrease in ALDH1A1 mRNA expression ( Figure 5C ). We validated that the superenhancer region is enriched in BRD4 and Pol II binding, another feature of super-enhancers (35) (Figure 5D ). Further, we validated the enrichment of H3K27Ac and H3K4Me1 epigenetic histone modifications in the putative super-enhancer regions ( Figure 5E ). Finally, knockdown of BRD4 expression was sufficient to decrease the eRNA expression, which correlated with the decrease in ALDH1A1 mRNA ( Figure 5F ). To directly determine whether the eRNA regulates ALDH1A1 mRNA expression, we knocked down the eRNA expression using siRNAs (36, 37) . Knockdown of the eRNA downregulated ALDH1A1 mRNA expression ( Figure 5G ), which correlated with a decrease in ALDH activity ( Figure  5H ). Notably, there was a significant positive correlation between BRD4, eRNA and ALDH1A1 expression in a panel of 26 cases of HGSC specimens ( Figure 5I-K) . This further highlights the established regulation of eRNA by BRD4 and subsequent ALDH1A1 expression by eRNA.
An important component of enhancer function is the formation of chromatin looping, allowing enhancer and promoter interaction (36, 38, 39) . We directly examined chromatin looping between the super-enhancer and ALDH1A1 gene promoter using chromosome conformation capture (3C) in cells with or without JQ1 treatment. We observed a robust association between the super-enhancer and the promoter region of the ALDH1A1 gene (Figure 5L-M) . Remarkably, JQ1 treatment abrogated the chromatin looping between the super-enhancer and the promoter of ALDH1A1 gene ( Figure 5M ). These results support the notion that JQ1 regulates transcription of ALDH1A1 through the newly identified superenhancer.
JQ1 inhibits expression of ALDH1A1 and its associated eRNA induced by cisplatin in vivo and combination of JQ1 and cisplatin improves survival
BET inhibitors have been proven safe in patients (40) . ALDH positive cells contribute to tumor progression and relapse after initial response to chemotherapy (3, 8) . To determine the effects of BET inhibitor on tumor relapse after cisplatin treatment, we orthotopically transplanted luciferase-expressing OVCAR3 cells into the peritoneal cavity of immunocompromised NOD/scid gamma (NSG) female mice. The injected cells were allowed to grow for 3 weeks to establish tumors. We randomly assigned mice into four groups and treated mice with: vehicle control (n=12), cisplatin (750 μg/kg every two weeks, n=12), JQ1 (20 mg/kg daily, n=11) and a combination of cisplatin and JQ1 (n=13) by intraperitoneal injection for an additional 4 weeks. Doses of JQ1 and cisplatin used were determined based on suppression of ALDH1A1 expression by JQ1 and regression of ovarian tumor in a pilot experiment ( Figure S6A-E) . Notably, the survival of the combination treated mice was significantly extended compared with mice treated with cisplatin alone ( Figure  6A ). We followed the tumor outgrowth/relapse in mice treated with cisplatin with or without JQ1 combination after stopping drug treatment. Indeed, the outgrowth of the tumors in the combination treatment group was significantly slower compared with the cisplatin only treatment group ( Figure 6B ). RNA from tumors harvested from the control and the three different treatment groups was utilized for qRT-PCR analysis. We observed that eRNA expression was induced by cisplatin alone (Figure 6C ), whereas JQ1 treatment suppressed the cisplatin-induced eRNA expression ( Figure 6C ). This correlated with changes in ALDH1A1 expression in these treatment groups ( Figure 6D and S6F ). ALDH1A1 mRNA expression was also significantly downregulated in JQ1 treated tumors ( Figure S6G ). Additionally, stem-related genes such as LIF and WNT5A were downregulated in JQ1/ cisplatin treated tumors ( Figure S6H ). However, BRD4 expression was not significantly changed in treatment groups ( Figure S6I ). Together, we conclude that a combination of JQ1 and cisplatin improves the survival of EOC bearing mice, which correlates with the suppression of expression of ALDH1A1 and its eRNA.
Discussion
Here, we found that BET inhibitors suppress ALDH activity. This correlates with suppression of ALDH1A1 expression by a BRD4 regulated super-enhancer and downregulation of its encoded eRNA ( Figure 6E ). BET inhibitors are now in clinical development and are safe. This suggests that BET inhibitors can be repurposed to target ALDH activity for improving platinum-based chemotherapy by inhibiting tumor relapse, a major challenge in the clinical management of EOC. Notably, BRD4 amplification/ overexpression is often mutually exclusive with "BRCAness" in EOC (25) . Thus, there is an even greater need for novel therapeutic strategies for this patient population given the limited therapeutic options available (2) . Our experiments clearly show that BET inhibitors, an existing class of epigenetic targeting drugs, target ALDH activity, potentiate the tumor suppression induced by cisplatin, and improve survival of EOC bearing mice in vivo. These findings will facilitate the rapid evaluation of this new strategy in the clinic for EOC.
BRD4 is a general transcriptional regulator that controls global gene expression patterns (12) . Investigation of genes hypersensitive to BET inhibition revealed that such genes typically exhibit BRD4 occupancy at super-enhancer elements (28) (29) (30) . This raises the possibility that BET inhibition is selective in gene regulation and thus confers relative specificity in a cell-context dependent manner. Our findings revealed that in response to JQ1 treatment, BRD4 assumes a key role in transcriptional control of the ALDH1A1 gene through regulating its super-enhancer and the associated eRNA. Although BRD4 plays a key role in regulating ALDH1A1 transcription, there are potentially other mechanisms than BRD4 expression levels that regulate ALDH1A1 expression (12) . BRD4 plays a key role in CSCs by selectively regulating the ALDH1A1 super-enhancer. In this context, BET inhibitors may selectively target CSCs by their effect on the ALDH1A1 super-enhancer. In addition to suppressing ALDH1A1 expression and ALDH activity, JQ1 also directly suppresses the expression of stem-related genes through reducing BRD4's association with their promoters (Figure 4) . Thus, the mode of action of BET inhibitors is multifaceted and likely involves a broad range of changes in transcription and the associated signaling pathways ( Figure 6E ). Given the established role of ALDH1A1 in ovarian CSCs (4), our data support the idea that the BRD4-regulated ALDH1A1 super-enhancer plays a key role in the observed phenotypes induced by BET inhibitors.
Our studies demonstrate that targeting BRD4 activity through the use of clinically applicably BET inhibitors represents a novel strategy for targeting ALDH activity. This correlates with suppression of ALDH1A1 expression via a BRD4-regulated super-enhancer and its associated eRNA. Given that there is currently no clinically applicable ALDH activity inhibitor, we expect our finding to have far-reaching implications for developing future therapeutic strategies using epigenetic targeting BET inhibitors in cancers such as EOC.
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